• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Biomaterial-based delivery platforms for transdermal immunotherapy
Biomed Pharmacother. 2023 Jun 27;165:115048. doi: 10.1016/j.biopha.2023.115048. Online ahead of print.ABSTRACTNowadays, immunotherapy is one of the most essential treatments for various diseases and a broad spectrum of disorders are assumed to be treated by altering the function of the immune system. For this reason, immunotherapy has attracted a great deal of attention and numerous studies on different approaches for immunotherapies have been investigated, using multiple biomaterials and carriers, from nanoparticles (NPs) to microneedles (MNs). In this review, the immunotherapy strategies, biomaterials, devices, and disea...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 29, 2023 Category: Drugs & Pharmacology Authors: Mohammad Dahri Nima Beheshtizadeh Nasrin Seyedpour Amin Nakhostin-Ansari Faezeh Aghajani Simin Seyedpour Moein Masjedi Fatemeh Farjadian Reza Maleki Khosro Adibkia Source Type: research

Immunization with placenta-specific 1 (plac1) induces potent anti-tumor responses and prolongs survival in a mouse model of melanoma
CONCLUSION: Our results pave the way for development of effective melanoma preventive vaccine in humans, although further studies are needed.PMID:36084365 | DOI:10.1016/j.advms.2022.08.002
Source: Advances in Medical Sciences - September 9, 2022 Category: Biomedical Science Authors: Shaghayegh Rahdan Seyed Alireza Razavi Sorour Shojaeian Fazel Shokri Mohammad Mehdi Amiri Amir-Hassan Zarnani Source Type: research

From “Serum Sickness” to “Xenosialitis”: Past, Present, and Future Significance of the Non-human Sialic Acid Neu5Gc
Conclusions and Perspectives In this review, we have discussed important milestones from the early description of “Serum-sickness” as being due to antibodies directed against Neu5Gc epitopes all the way to the present-day therapeutic implications of these antibodies in cancer therapy. Some of these milestones have been represented in a concise timeline (Figure 6). While the “Xenosialitis” hypothesis is well-supported in the human-like mouse models, it has yet to be conclusively proven in humans. It remains to be seen if “Xenosialitis” plays a role in other uniquely-human dis...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research